Carbohydrates and T cells: A sweet twosome

Seminars in Immunology

Volumn 25, Issue 2, 2013, Pages 146-151

  Avci, Fikri Y ^a,b   Li, Xiangming ^c   Tsuji, Moriya ^c   Kasper, Dennis L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antigen presentation; Glycoconjugate vaccine; Glycolipid; Glycopeptide; T cell; Zwitterionic polysaccharide

Indexed keywords

BACTERIAL POLYSACCHARIDE; CARBOHYDRATE; CARBOHYDRATE ANTIGEN; GLYCOCONJUGATE; GLYCOLIPID; GLYCOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOSACCHARIDE; OLIGOSACCHARIDE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BACTEROIDES FRAGILIS; CARBOHYDRATE ANALYSIS; CD4+ T LYMPHOCYTE; HAEMOPHILUS INFLUENZAE; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENT CELL; LYMPHOCYTE; NATURAL KILLER T CELL; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 TH2 BALANCE;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; APCS; B-CELL RECEPTOR; BCR; CAPSULAR POLYSACCHARIDES; CPSS; DCS; DENDRITIC CELLS; GBSIII; GLYCOCONJUGATE VACCINE; GLYCOLIPID; GLYCOPEPTIDE; IBD; IFN-Γ; IL; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMATORY BOWEL DISEASE; INKT; INOS; INTERFERON Γ; INTERLEUKIN; INVARIANT NATURAL-KILLER T; MAJOR HISTOCOMPATIBILITY CLASS II; MHCII; OVA; OVALBUMIN; POLYSACCHARIDE A; PSA; REACTIVE NITROGEN SPECIES; RNSS; T CELL; T CELLS THAT RECOGNIZE CARBOHYDRATES ONLY; T-CELL RECEPTOR; TCARBS; TCR; TETANUS TOXOID; TT; TYPE III POLYSACCHARIDE OF GROUP B STREPTOCOCCUS; ZPSS; ZWITTERIONIC POLYSACCHARIDE; ZWITTERIONIC POLYSACCHARIDES; Α-GALACTOSYLCERAMIDE.; Α-GALCER;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1D; CARBOHYDRATES; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VACCINES, CONJUGATE;

EID: 84882267659     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.05.005     Document Type: Review

References (75)

1. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annual Review of Immunology 2004, 22:817-890.
2. Dzhambazov B., Holmdahl M., Yamada H., Lu S., Lestberg M., Holm B., et al. The major T cell epiope on type II collagen is glycosylated ion normal cartilage but modified by arthritis in both rats and humans. European Journal of Immunology 2005, 35:357-366.
3. Cobb B.A., Wang Q., Tzianabos A.O., Kasper D.L. Polysaccharide processing and presentation by the MHCII pathway. Cell 2004, 117:677-687.
4. Avci F.Y., Kasper D.L. How bacterial carbohydrates influence the adaptive immune system. Annual Review of Immunology 2010, 28:29-52.
5. Avci F.Y., Li X.M., Tsuji M., Kasper D.L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nature Medicine 2011, 17:1602-1610.
6. Duan J., Avci F.A., Kasper D.L. Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII. Proceedings of the National Academy of Sciences of United States of America 2008, 105:5183.
7. Cobb B.A., Kasper D.L. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Glycobiology 2008, 18:707.
8. Stingele F., Corthesy B., Kusy N., Porcelli S.A., Kasper D.L., Tzianabos A.O. Zwitterionic polysaccharides stimulate T cells with no preferential vbeta usage and promote anergy. Resulting in protection against experimental abscess formation. Journal of Immunology 2004, 172:1483-1490.
9. Groneck L., Schrama D., Fabri M., Stephen T.L., Harms F., Meemboor S., et al. Oligoclonal CD4+ T cells promote host memory immune responses to zwitterionic polysaccharide of Streptococcus pneumoniae. Infection and Immunity 2009, 77:3705-3712.
10. Ovodov Y.S. Bacterial capsular antigens, structural patterns of capsular antigens. Biochemistry (Moscow) 2006, 71:937-954.
11. Coutinho A., Moller G. B cell mitogenic properties of thymus-independent antigens. Nature New Biology 1973, 245:12-14.
12. Barrett D.J. Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants. Advances in Pediatrics 1985, 32:139-158.
13. Guttormsen H.-K., Sharpe A.H., Chandraker A.K., Brigtsen A.K., Sayegh M.H., Kasper D.L. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infection and Immunity 1999, 67:6375-6384.
14. Guttormsen H.K., Wetzler L.M., Finberg R.W., Kasper D.L. Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model. Infection and Immunity 1998, 66:2026.
15. Velez C.D., Lewis C.J., Kasper D.L., Cobb B.A. Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology 2009, 127:73-82.
16. Stephen T.L., Fabri M., Groneck L., Roehn T.A., Hafke H., Robinson N., et al. Transport of Streptococcus pneumoniae capsular polysaccharide in MHC class II tubules. PLoS Pathogens 2007, 3.
17. Trück J., Lazarus R., Clutterbuck E.A., Bowman J., Kibwana E., Bateman E.A., et al. The zwitterionic type I Streptococcus pneumoniae polysaccharide does not induce memory B cell formation in humans. Immunobiology 2013, 218:368-372.
18. Tzianabos A.O., Wang J.Y., Lee J.C. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proceedings of the National Academy of Sciences of United States of America 2001, 98:9365-9370.
19. McLoughlin R.M., Lee J.L., Kasper D.L., Tzianabos A.O. IFN-γ regulated chemokine production determines the outcome of Staphylococcus aureus infection. Journal of Immunology 2008, 181:1323-1332.
20. Mazmanian S.K., Liu C.H., Tzianabos A.O., Kasper D.L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005, 122:107-118.
21. Mazmanian S.K., Kasper D.L. The love-hate relationship between bacterial polysaccharides and the host immune system. Nature Reviews Immunology 2006, 6:849-858.
22. Mazmanian S.K., Round J.L., Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
23. Surana N.K., Kasper D.L. The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA. Immunological Reviews 2012, 245:13-26.
24. Tzianabos A.O., Kasper D.L., Cisneros R.L., Smith R.S., Onderdonk A.B. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. Journal of Clinical Investigation 1995, 96:2727-2731.
25. Tzianabos A.O., Onderdonk A.B., Smith R.S., Kasper D.L. Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infection and Immunity 1994, 62:3590-3593.
26. Tzianabos A.O., Russell P.R., Onderdonk A.B., Gibson F.C., Cywes C., Chan M., et al. IL-2 mediates protection against abscess formation in an experimental model of sepsis. Journal of Immunology 1999, 163:893-897.
27. Tzianabos A.O., Finberg R.W., Wang Y., Chan M., Onderdonk A.B., Jennings H.J., et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. Journal of Biological Chemistry 2000, 275:6733-6740.
28. Mitchison N.A. The carrier effect in the secondary response to hapten-protein conjugates II. Cellular cooperation. European Journal of Immunology 1971, 1:18-25.
29. Mitchison N.A. The carrier effect in the secondary response to haptenprotein conjugates I. Measurement of the effect with transferred cells and objections to the local environment hypothesis. European Journal of Immunology 1971, 1:10-17.
30. Beuvery E.C., Van Rossum F., Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type III and meningococcal group C polysaccharides and their protein conjugates. Infection and Immunity 1982, 37:15-22.
31. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. Journal of Experimental Medicine 1980, 152:361-376.
32. Wessels M.R., Paoletti L.C., Rodewald A.K., Michon F., DiFabio J., Jennings H.J., et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infection and Immunity 1993, 61:4760-4766.
33. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydrate Research 2003, 338:2539-2547.
34. Mitchison N.A. T-cell-B-cell cooperation. Nature Reviews Immunology 2004, 4:308-312.
35. Trotter C.L., McVernon J., Ramsay M.E., Whitney C.G., Mulholland E.K., Goldblatt D., et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008, 26:4434-4445.
36. Avci F.Y., Li X., Tsuji M., Kasper D.L. Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines. Nature Protocols 2012, 7:2180-2192.
37. Janeway C.A., Travers P., Walport M., Chlomchik M. Immunobiology 2005, Garland Science Publishing, New York. 6th ed.
38. Deck B., Elofsson M., Kihlberg J., Unanue E.R. Specificity of glycopeptide-specific T cells. Journal of Immunology 1995, 155:1074-1078.
39. Mouritsen S., Meldal M., Christiansenbrams I., Elsner H., Werdelin O. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex Class-II molecules and peptide immunogenicity. European Journal of Immunology 1994, 24:1066-1072.
40. Haurum J.S., Arsequell G., Lellouch A.C., Wong S.Y.C., Dwek R.A., McMichael A.J., et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T-lymphocytes. Journal of Experimental Medicine 1994, 180:739-744.
41. Haurum J.S., Tan L., Arsequell G., Frodsham P., Lellouch A.C., Moss P.A.H., et al. Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. European Journal of Immunology 1995, 25:3270-3276.
42. AbdelMotal U.M., Berg L., Rosten A., Bengtsson M., Thorpe C.J., Kihlberg J., et al. Immunization with glycosylated K-b-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. European Journal of Immunology 1996, 26:544-551.
43. Ishioka G.Y., Lamont A.G., Thomson D., Bulbow N., Gaeta F.C.A., Sette A., et al. MHC interaction and T-cell recognition of carbohydrates and glycopeptides. Journal of Immunology 1992, 148:2446-2451.
44. Werdelin O., Meldal M., Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proceedings of the National Academy of Sciences of United States of America 2002, 99:9611-9613.
45. Corthay A., Backlund J., Broddefalk J., Michaelsson E., Goldschmiddt T., Kilberg J., et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. European Journal of Immunology 1998, 28:2580-2590.
46. Harding C.V., Kihlberg J., Elofsson M., Magnusson G., Unanue E.R. Glycopeptides bind MHC molecules and elicit specific T-cell responses. Journal of Immunology 1993, 151:2419-2425.
47. Gad M., Werdelin O., Meldal M., Komba S., Jensen T. Characterization of T cell hybridomas raised against a glycopeptide containing the tumor-associated T antigen (beta Gal (1-3) alpha GalNAc-O/Ser). Glycoconjugate Journal 2002, 19:59-65.
48. GalliStampino L., Meinjohanns E., Frische K., Meldal M., Jensen T., Werdelin O., et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Research 1997, 57:3214-3222.
49. Ingale S., Awolfert M., Gaekwad J., Buskas T., Boons G.J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nature Chemical Biology 2007, 3:663-667.
50. Bendelac A., Rivera M.N., Park S.H., Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annual Review of Immunology 1997, 15:535-562.
51. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annual Review of Immunology 2005, 23:877-900.
52. Sieling P.A., Chatterjee D., Porcelli S.A., Prigozy T.I., Mazzaccaro R.J., Soriano T., et al. Cd1-restricted T-cell recognition of microbial lipoglycan antigens. Science 1995, 269:227-230.
53. Moody D.B., Reinhold B.B., Guy M.R., Beckman E.M., Frederique D.E., Furlong S.T., et al. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science 1997, 278:283-286.
54. Kawano T., Cui J.Q., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of V(alpha)14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
55. Brossay L., Chioda M., Burdin N., Koezuka Y., Casorati G., Dellabona P., et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. Journal of Experimental Medicine 1998, 18:1521-1528.
56. Koch M., Stronge V.S., Shepherd D., Gadola S.D., Mathew B., Ritter G., et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nature Immunology 2005, 6:819-826.
57. Borg N.A., Wun K.S., Kjer-Nielsen L., Wilce M.C.J., Pellicci D.G., Koh R., et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007, 448:44-49.
58. Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cellular and Molecular Life Sciences 2006, 63:1889-1898.
59. Kawano T., Cui J.Q., Koezuka Y., Toura I., Kaneko Y., Sato H., et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V alpha 14 NKT cells. Proceedings of the National Academy of Sciences of United States of America 1998, 95:5690-5693.
60. Crowe N.Y., Smyth M.J., Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. Journal of Experimental Medicine 2002, 196:119-127.
61. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nature Medicine 2001, 7:1052-1056.
62. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nature Medicine 2001, 7:1057-1062.
63. Jahng A.W., Maricic I., Pedersen B., Burdin N., Naidenko O., Kronenberg M., et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2001, 194:1789-1799.
64. Singh A.K., Wilson M.T., Hong S.M., Olivares-Villagomez D., Du C.G., Stanic A.K., et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2001, 194:1801-1811.
65. Kakimi K., Guidotti L.G., Koezuka Y., Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. Journal of Experimental Medicine 2000, 192:921-930.
66. Chackerian A., Alt J., Perera V., Behar S.M. Activation of NKT cells protects mice from tuberculosis. Infection and Immunity 2002, 70:6302-6309.
67. Kawakami K., Kinjo Y., Yara S., Koguchi Y., Uezu K., Nakayama T., et al. Activation of V alpha 14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infection and Immunity 2001, 69:213-220.
68. Gonzalez-Aseguinolaza G., de Oliveira C., Tomaska M., Hong S., Bruna-Romero O., Nakayama T., et al. Alpha-galactosylceramide-activated V alpha 14 natural killer T cells mediate protection against murine malaria. Proceedings of the National Academy of Sciences of United States of America 2000, 97:8461-8466.
69. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. Journal of Clinical Investigation 2004, 114:1800-1811.
70. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4(+) and CD8(+) T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. Journal of Immunology 2003, 171:5140-5147.
71. Fujii S., Shimizu K., Smith C., Bonifaz L., Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. Journal of Experimental Medicine 2003, 198:267-279.
72. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. Journal of Experimental Medicine 2002, 195:617-624.
73. Kopecky-Bromberg S.A., Fraser K.A., Pica N., Carnero E., Moran T.M., Franck R.W., et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 2009, 27:3766-3774.
74. Li X.M., Fujio M., Imamura M., Wu D., Vasan S., Wong C.H., et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proceedings of the National Academy of Sciences of United States of America 2010, 107:13010-13015.
75. Padte N.N., Li X.M., Tsuji M., Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clinical Immunology 2011, 140:142-151.